• ABOUT
  • TEAM
  • SERVICES
  • RESULTS
  • NEWS
  • CAREERS

Plexus Ventures Assists Glenmark Pharmaceuticals to Divest a CNS Product Portfolio and Commercial Team in Poland to Neuraxpharm

by plexusventures_h3tnl0 | Apr 7, 2020 | Featured

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the completion of a divestiture project on behalf of its client, Glenmark Pharmaceuticals Ltd. Plexus Ventures advised Glenmark on the sale of a CNS product portfolio and sales team to Neuraxpharm....

Plexus Ventures advises Cinfa Group in PLG’s “Deal of the Year”

by plexusventures_h3tnl0 | Mar 26, 2019 | Featured

London, England – The Pharmaceutical Licensing Group, whose mission is promote and support excellence in deal making across the healthcare industry, recently awarded Mundipharma International its inaugural “PLG Deal of the Year” for its acquisition of Cinfa Biotech....

Plexus Ventures Assists Laboratorios Cinfa in Selling Biosimilar Business to Mundipharma

by plexusventures_h3tnl0 | Oct 11, 2018 | Featured

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a divestiture project for its client, Laboratorios Cinfa, S.A. of Pamplona, Spain. Plexus Ventures advised Cinfa on the sale of its biosimilar business, Cinfa Biotech to a...

Mabion S.A. completes marketing authorization application for flagship drug, MabionCD20, to the European Medicines Agency (EMA)

by plexusventures_h3tnl0 | Jun 5, 2018 | Featured

Plexus Ventures would like to share successful news from Mabion S.A. Additional details are provided in Mabion’s press release (Konstantynów Łódzki, 1.06.2018): • Company submitted the marketing authorization application under the centralized authorization procedure...

Recent Posts

  • Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody
  • Celon Pharma enters agreement with Zydus Lifesciences Ltd.
  • Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses
  • Plexus Ventures’ Important Company Announcement
  • Plexus Ventures Assists Valeas S.p.A. to acquire from Pharmactive Biotech Products, SL, Spain licensing and distribution rights for its premium Affron®-based product for commercialization in Italy

Recent Comments

    Collaborating with clients to grow their businesses; committing our experience, resources and time to their success.

    Business Builders in Healthcare

    Contact Us
    • Follow
    • Follow

    About Us

    Our Team

    Areas of Expertise

    Project Portfolio

    What’s Trending

    Join Plexus